Effects of Particulate Matter on the Pulmonary Function and Acute Exacerbation of COPD and Asthma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03193879|
Recruitment Status : Unknown
Verified June 2017 by Peking Union Medical College Hospital.
Recruitment status was: Recruiting
First Posted : June 21, 2017
Last Update Posted : June 27, 2017
|Condition or disease|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||500 participants|
|Target Follow-Up Duration:||2 Years|
|Official Title:||Effects of Particulate Matter on the Lung Function and Acute Exacerbation of COPD and Asthma Patients－－A Multi-center Cohort Study|
|Actual Study Start Date :||December 2015|
|Estimated Primary Completion Date :||August 2019|
|Estimated Study Completion Date :||August 2019|
- Change in spirometry (FEV1) of COPD, asthma patients and healthy volunteers in response to different exposure doses of PM. [ Time Frame: 2 years ]Spirometry will be assessed at baseline and through study completion, an average of 2 years.
- Change in morbidity of acute exacerbation in COPD and asthma patients in response to different exposure doses of PM. [ Time Frame: 2 years ]Patients will be followed up through study completion, an average of 2 years.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03193879
|Contact: Kai-Feng Xu, M.D.||firstname.lastname@example.org|
|Contact: Xinlun Tian, M.D.||email@example.com|
|Peking Union Medical College Hospital||Recruiting|
|Beijing, Beijing, China, 100730|
|Contact: Kai-Feng Xu, M.D. 86-10-69155039 firstname.lastname@example.org|
|Contact: Xinlun Tian, M.D. 86-10-69155039 email@example.com|
|Sub-Investigator: Xinlun Tian, M.D.|
|Principal Investigator: Kai-Feng Xu, M.D.|